Intra-Cellular Slumps to 2-Year Low as Schizophrenia Study FailsBy and
Drug was in the third and final stage of testing for approval
Shares down as much as 65%, biggest intraday drop ever
Intra-Cellular Therapies Inc. shares plummeted to their lowest level in almost two years after its lead drug, an experimental pill for treating schizophrenia, failed to help patients in a key late-stage study.
To continue reading this article you must be a Bloomberg Professional Service Subscriber.
If you believe that you may have received this message in error please let us know.